Bionano Genomics Inc.

Bionano Genomics Inc. (NASDAQ: BNGO) is a life sciences instrumentation company in the genome analysis space. The group develops and distributes the Saphyr system, a platform used for ultra-sensitive and ultra-specific structural variation detection. The above system enables researchers and clinicians to enhance the detection of new diagnostics and therapeutic targets and to simplify the study of changes in chromosomes.

Key Highlights:

• Negative Cash flows: The company reported cash used in operating activities of USD 13.904 million, which stood higher from USD 8.032 million a year ago. The above was primarily due to a net loss which occurred in the current quarter.

• Impressive result from Optical Genome Mapping (OGM): The company reported that it received results from University Hospitals Leuven, Belgium, for its optical genome mapping (OGM) with Bionano’s Saphyr ^® system, which is used for acute lymphoblastic leukemia disease. The report highlighted faster turnaround time, higher success rates v/s traditional methods, and lower cost per sample. 
  

Q1FY21 Financial Highlights:

• BNGO announces its quarterly result, wherein the company posted total revenue of USD 3.168 million, surged from USD 1.136 million in the previous corresponding period (pcp). The growth was supported from both the company’s revenue stream.
• Cost of revenue jumped to USD 2.125 million, from USD 0.856 million in the previous corresponding period (pcp). The company reported a higher selling, general and administrative expense due to a surge in the headcount-related costs due to the acquisition of Lineagen.
• Research and development expenses stood at USD 2.678 million, at par with USD 2.674 million in pcp.
• The company reported a net loss of USD 9.947 million, as compared to USD 10.510 million in pcp.

Q1FY21 Income Statement Highlights (Source: Company Report)

Risks: In order to support the company’s growth prospects, the group would require additional funding as the corporation is incurring losses from its existing operations. Moreover, any delay in the regulatory approvals would dampen the company’s overall performance.

Stock Recommendation:

The company reported an encouraging topline in the first quarter of FY21 but failed to retain the momentum in its bottom line. Moreover, a surge in the input costs due to the new acquisition has dampened the company’s operations. Additionally, the Management highlighted that its operations were negatively impacted due to the travel restriction imposed on account of COVID-19, and further imposition of restriction would pose a threat to the company’s operations. The stock of BNGO declined ~22% and ~30% in the last one month and six months, respectively, and closed below the immediate support levels of 50-days and 100-days simple moving averages (SMA), respectively, indicating a bearish pattern. Considering the above facts, we give a ‘Watch’ rating on the stock at the closing price of USD 5.90 on July 19, 2021.

One-Year Technical Price Chart (as on June 19, 2021). Source: REFINITIV, Analysis by Kalkine Group

*The reference data in this report has been partly sourced from REFINITIV.

Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.

Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.

You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.

Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine do not hold interests in any of the securities or other financial products covered on the Kalkine website.